Your session is about to expire
← Back to Search
Study Summary
This trial will help researchers learn more about the safety and effectiveness of vedolizumab in children and teenagers with Crohn's disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 278 Patients • NCT03029143Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with indeterminate colitis.I weigh at least 10 kg.I've had severe colitis for over 8 years and had a colonoscopy in the last year.I've tried and not responded well to certain medications for my condition.I have not had a serious infection like pneumonia or COVID-19 in the last 30 days.I have had significant surgery on my intestines.I haven't taken any experimental or approved biologic treatments recently.I have had cancer other than some skin cancers or early-stage cervical cancer.I tested negative for hepatitis B surface antigen but positive for core antibody, and do not have hepatitis B virus DNA.I have been tested positive for hepatitis B or have immunity against it.I have signs of a genetic form of very early-onset IBD.I have a condition that weakens my immune system, such as HIV.I have been diagnosed with Crohn's disease over a month ago and it is moderately to severely active.I have chronic hepatitis C.I do not have active brain disorders or a history of serious neurological conditions.My Crohn's disease is active and not responding to current treatments.I have not received any live vaccines in the last 30 days.I need or might need surgery for Crohn's disease during the study.
- Group 1: Maintenance Period: 10 to 15 kg Vedolizumab 100 mg
- Group 2: Maintenance Period: >15 to <30 kg, Vedolizumab 200 mg
- Group 3: Maintenance Period: >15 to <30 kg Vedolizumab 100 mg
- Group 4: Induction Period: >15 to <30 kg, Vedolizumab 200 mg
- Group 5: Maintenance Period: 10 to 15 kg Vedolizumab 150 mg
- Group 6: Maintenance Period: ≥30 kg, Vedolizumab 300 mg
- Group 7: Induction Period: 10 to 15 kg, Vedolizumab 150 mg
- Group 8: Induction Period: ≥30 kg, Vedolizumab 300 mg
- Group 9: Maintenance Period: ≥30 kg: Vedolizumab 150 mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this a new study?
"As of now, there are 23 active clinical trials for Vedolizumab IV in 312 different cities across 42 countries. The first study was conducted in 2015 and involved 260 patients. It completed Phase 4 drug approval stage successfully. In the years since then, 38 more studies have been carried out."
Has Vedolizumab IV received permission from the FDA for general use?
"3."
Do we have a lot of data points for this research in Canada?
"Right now, this clinical trial is taking place in 26 hospitals, with locations ranging from Edmonton to Rochester. To try and limit participant burden, it is recommended you select a site close to your home."
Are we looking for new participants in this experiment at the moment?
"The clinical trial is currently seeking patients that fit the study's criteria. The original posting date was April 30th, 2022 and the most recent update was on August 25th, 2022. In total, 26 different medical facilities are participating in this research project which needs a total of 120 enrollees."
What other drugs have been administered in tandem with Vedolizumab IV?
"Vedolizumab IV was first researched in 2015 at AZ Delta Roeselare. Since then, there have been 38 completed clinical trials worldwide. As of now, 23 active studies are being conducted; a significant number of these are based in Edmonton, Alberta."
Does this experiment have any age restrictions?
"This clinical trial is looking for pediatric patients that are older than 2 but younger than 17 years of age."
How can I become a participant in this research?
"This trial is currently recruiting 120 pediatric patients that have been diagnosed with crohn disease. Key inclusion criteria for this study are as follows: The participants has moderately to severely active CD, unresponsive or intolerant to their current standard of care (SOC)., The participants weigh ≥10 kg at the time of screening and enrollment into the study., Participants with moderately to severely active Crohn's disease (CD) diagnosed at least 1 month before screening, defined by a Pediatric Crohn's Disease Activity Index (PCDAI) >30 and an simple endoscopic score for Crohn's Disease (SES-CD) >6 ("
How many people are currently signed up for this experiment?
"That is correct, the study is currently enrolling patients. The trial was initially posted on 4/30/2022, with the most recent update being on 8/25/2022. So far, 26 sites have been recruited to help find the 120 total patients needed for the study."
Share this study with friends
Copy Link
Messenger